Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

Dr. Carl  Spana Ph.D.

Co-Founder, President, Chief Executive Officer & Director

Mr. James E. Hattersley

Senior Vice President of Business Development

Mr. John  Dodd Ph.D.

Senior Vice President of Preclinical Development

Burns  McClellan

Vice President of Investor Relations

Mr. Stephen A. Slusher Esq.

Chief Legal Officer

Dr. Michael B. Raizman M.D.

Chief Medical Officer

Mr. Robert  Jordan

Senior Vice President of Program Operations

生物技术

Palatin Technologies, Inc.

Palatin Technologies, Inc. 管理结构

管理层信息